In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 13, 2021
CMIC Joins DTRA as a Founding Company
Author(s)BioPharm International Editors
CMIC will work to advance decentralized trials in Japan.
Advertisement
CMIC, a Japanese contract resource organization (CRO), announced on Jan. 12, 2021 that it has joined the Decentralized Trials and Research Alliance (DTRA), an organization aiming to accelerate the adoption of decentralized clinical trials, as a founding company.
By joining as a founding company, CMIC will become a part of the DTRA Leadership Council and will begin advancing decentralized trials in Japan by establishing its connection with organizations and companies in the United States, CMIC said in a company press release.
“By joining the Leadership Council, CMIC will be able to study real-world examples of decentralized clinical trials that are led in the US, and network with US organizations,” said Toru Fujieda, president of CMIC, in the press release. “Through this, CMIC will be able to formulate realistic and efficient studies within the Japanese clinical trial environment and propose solutions for challenges that arise during a trial. As a member of DTRA, we will leverage the latest global digital health technology to the fullest and contribute to smooth decentralized trial conduct in Japan. Furthermore, as the largest Japanese CRO with a broad Asian footprint, we will bring our decentralized trial adoption experiences, trends, and needs of the fast-growing Asian market into DTRA, in order to facilitate the development of future global standards.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5